Changes in Beneficial Ownership · 4
MBX Biosciences, Inc.
MBXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-20
- Issuer
- MBX Biosciences, Inc.
- Issuer CIK
- 0001776111
- Trading symbol
- MBX
Reporting owner 1
- Name
- Radovich Peter
- Reporting owner CIK
- 0001650131
- Relationship
- Director
- Address
- 11711 N. MERIDIAN STREET, SUITE 300, CARMEL, IN, 46032
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy) | 53.50 | 2026-10-20 | A · Form 4 | 18,200 | A | 0 | [F1] | 2036-10-20 | Common Stock | 18,200 | 18,200 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- One-third of the shares underlying this option will vest and become exercisable on October 20, 2027, the anniversary of the date of grant, with the remainder vesting monthly over the subsequent two year period, subject to the Reporting Person's continued service on each such vesting date.↩ 1
Signature 1
- Signed
- /s/ Steven L. Hoerter
- Date
- 2026-10-22
Company context
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEP™, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. Our product candidates and programs include:
Current securities
Recent company filings
- 3 filingOct 22, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 22, 2026
- Regulation FD Disclosure · Other EventsAug 27, 2026
- SCHEDULE 13G/A - filed by Deep Track Capital, LP regarding MBX Biosciences, Inc.Aug 14, 2026
- 10-Q filingAug 6, 2026